ECSP045060A - Nuevas formulaciones analogas de ciclosporina - Google Patents

Nuevas formulaciones analogas de ciclosporina

Info

Publication number
ECSP045060A
ECSP045060A EC2004005060A ECSP045060A ECSP045060A EC SP045060 A ECSP045060 A EC SP045060A EC 2004005060 A EC2004005060 A EC 2004005060A EC SP045060 A ECSP045060 A EC SP045060A EC SP045060 A ECSP045060 A EC SP045060A
Authority
EC
Ecuador
Prior art keywords
cyclosporin
formulas
analog formulations
cyclosporine analog
analogs
Prior art date
Application number
EC2004005060A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045060A publication Critical patent/ECSP045060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)

Abstract

El presente invento se relaciona con fórmulas que contengan análogos de ciclosporina que sean estructuralmente similares a la ciclosporina A, en particular mezclas isómeras de análogos de ciclosporina que sean estructuralmente similares a la ciclosporina A. Las fórmulas forman pre-concentrados de micro-emulsiones estables y pueden proporcionar bio-disponibilidad de medicamento superior y/o podrán reducir uno o más de los efectos perjudiciales asociados con la administración de ciclosporina. También se divulgan los métodos para utilizar y preparar las fórmulas.
EC2004005060A 2001-10-19 2004-04-14 Nuevas formulaciones analogas de ciclosporina ECSP045060A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19

Publications (1)

Publication Number Publication Date
ECSP045060A true ECSP045060A (es) 2004-07-23

Family

ID=23358378

Family Applications (3)

Application Number Title Priority Date Filing Date
EC2004005061A ECSP045061A (es) 2001-10-19 2004-04-14 Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores
EC2004005059A ECSP045059A (es) 2001-10-19 2004-04-14 Sintesis de analogos de ciclosporina
EC2004005060A ECSP045060A (es) 2001-10-19 2004-04-14 Nuevas formulaciones analogas de ciclosporina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EC2004005061A ECSP045061A (es) 2001-10-19 2004-04-14 Mezclas analogas de ciclosporina y su uso como agentes inmunomoduladores
EC2004005059A ECSP045059A (es) 2001-10-19 2004-04-14 Sintesis de analogos de ciclosporina

Country Status (38)

Country Link
US (2) US20110092669A1 (es)
EP (2) EP1436322B1 (es)
JP (4) JP2005511538A (es)
KR (1) KR100992850B1 (es)
CN (1) CN100344648C (es)
AR (1) AR036853A1 (es)
AT (1) ATE401339T1 (es)
AU (1) AU2002331510B2 (es)
BE (1) BE2022C547I2 (es)
BR (1) BR0213659A (es)
CA (2) CA2727642C (es)
CO (1) CO5570682A2 (es)
CY (2) CY1108410T1 (es)
DE (1) DE60227686D1 (es)
DK (1) DK1436322T3 (es)
EC (3) ECSP045061A (es)
ES (1) ES2310604T3 (es)
FI (1) FIC20220041I1 (es)
FR (1) FR22C1051I2 (es)
HR (1) HRP20040353B1 (es)
IL (2) IL160762A0 (es)
LT (1) LTC1436322I2 (es)
MA (1) MA26337A1 (es)
ME (1) ME00487B (es)
MX (1) MXPA04003624A (es)
MY (1) MY187182A (es)
NL (1) NL301200I2 (es)
NO (2) NO331745B1 (es)
NZ (1) NZ531945A (es)
PL (1) PL210697B1 (es)
PT (1) PT1436322E (es)
PY (2) PY0225477A (es)
RU (1) RU2337106C2 (es)
SI (1) SI1436322T1 (es)
TN (1) TNSN04069A1 (es)
UY (1) UY27502A1 (es)
WO (1) WO2003033527A2 (es)
ZA (1) ZA200402270B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033526A2 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
ES2310604T3 (es) * 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
CA2592343A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
CA2623898C (en) * 2005-10-26 2013-12-24 Astellas Pharma Inc. New cyclic peptide compounds
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ES2396170T3 (es) * 2007-05-02 2013-02-19 Astellas Pharma Inc. Nuevos compuestos péptídicos ciclicos
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
RU2361604C1 (ru) * 2007-10-29 2009-07-20 Федеральное агентство по высокотехнологичной медицинской помощи Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" (ФГУ УрНИИДВиИ Росмедтехнологий) Способ лечения атопического дерматита
WO2010144194A1 (en) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
JP6144627B2 (ja) 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク． アミノ酸１および３で修飾されたシクロスポリン類似体分子
GB201222455D0 (en) 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
JP2020510249A (ja) * 2016-11-30 2020-04-02 シュレーディンガー インコーポレイテッドＳｃｈｒｏｄｉｎｇｅｒ，Ｉｎｃ． 化学の遷移状態を計算するためのグラフィカルユーザインタフェース
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018106928A1 (en) 2016-12-08 2018-06-14 Contravir Pharmaceuticals, Inc. Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3
WO2018112255A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US10286036B2 (en) * 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
IL296586B1 (en) * 2020-03-26 2026-04-01 Farsight Medical Tech Shanghai Co Ltd Cyclophilin inhibitors and their uses
EP4201952A1 (en) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Process for the controlled synthesis of voclosporin
EP4584279A1 (en) * 2022-09-09 2025-07-16 Dr. Reddy's Laboratories Limited Improved process for the preparation of voclosporin
IT202300001116A1 (it) * 2023-01-25 2024-07-25 Indena Spa Processo per la preparazione di un intermedio utile per la sintesi di voclosporina
IT202300001056A1 (it) * 2023-01-25 2024-07-25 Procos Spa Nuovo processo per la preparazione di voclosporina amorfa
WO2025119925A1 (en) 2023-12-05 2025-06-12 Medichem, S.A. Process for preparing voclosporin
IT202300028041A1 (it) * 2023-12-27 2025-06-27 Indena Spa Processo per la preparazione di voclosporina

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278545A (en) * 1979-09-12 1981-07-14 The Bendix Corporation Apparatus for separating solids and liquid components
CH670644A5 (es) * 1986-12-18 1989-06-30 Lonza Ag
US5162540A (en) * 1986-12-18 1992-11-10 Lonza Ltd. Process for the production of (+) biotin
ES2059558T3 (es) * 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
DK0869810T3 (da) * 1996-06-19 2005-02-07 Novartis Ag Cyclosporinholdige blöde kapselpræparater
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
WO2003033526A2 (en) * 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
ES2310604T3 (es) * 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.

Also Published As

Publication number Publication date
TNSN04069A1 (en) 2006-06-01
MXPA04003624A (es) 2004-12-06
JP5272140B2 (ja) 2013-08-28
UY27502A1 (es) 2003-04-30
ME00487B (me) 2011-10-10
CY1108410T1 (el) 2012-05-23
DE60227686D1 (de) 2008-08-28
MY187182A (en) 2021-09-08
FR22C1051I1 (fr) 2022-12-16
NO331745B1 (no) 2012-03-19
NO20042029L (no) 2004-05-14
JP2009197036A (ja) 2009-09-03
EP1436322A2 (en) 2004-07-14
HK1062567A1 (en) 2004-11-12
US20110092669A1 (en) 2011-04-21
PY0225477A (es) 2004-05-03
IL160762A (en) 2010-11-30
ECSP045059A (es) 2004-07-23
JP2011006417A (ja) 2011-01-13
MA26337A1 (fr) 2004-10-01
CA2727642C (en) 2014-02-04
CY2022030I2 (el) 2023-06-09
KR20050037421A (ko) 2005-04-21
LTPA2022521I1 (es) 2022-11-10
PL370501A1 (en) 2005-05-30
IL160762A0 (en) 2004-08-31
CN100344648C (zh) 2007-10-24
HRP20040353A2 (en) 2005-04-30
SI1436322T1 (sl) 2008-12-31
BR0213659A (pt) 2004-10-26
HRP20040353B1 (hr) 2012-10-31
NL301200I2 (nl) 2024-07-25
ATE401339T1 (de) 2008-08-15
PL210697B1 (pl) 2012-02-29
NZ531945A (en) 2006-01-27
LTC1436322I2 (es) 2023-06-26
BE2022C547I2 (es) 2022-10-19
JP2013136597A (ja) 2013-07-11
CA2460685A1 (en) 2003-04-24
FIC20220041I1 (fi) 2022-10-14
WO2003033527A3 (en) 2003-10-16
RU2337106C2 (ru) 2008-10-27
ECSP045061A (es) 2004-08-27
AR036853A1 (es) 2004-10-06
JP2005511538A (ja) 2005-04-28
CY2022030I1 (el) 2023-01-27
CO5570682A2 (es) 2005-10-31
AU2002331510B2 (en) 2008-05-01
CN1571794A (zh) 2005-01-26
FR22C1051I2 (fr) 2023-11-17
WO2003033527A2 (en) 2003-04-24
PT1436322E (pt) 2008-10-23
ES2310604T3 (es) 2009-01-16
US20140288266A1 (en) 2014-09-25
NO2022042I1 (no) 2022-10-14
DK1436322T3 (da) 2008-11-03
PY0225478A (es) 2004-05-03
CA2460685C (en) 2014-05-27
EP1816138A1 (en) 2007-08-08
CA2727642A1 (en) 2003-04-24
ZA200402270B (en) 2005-05-25
RU2004110941A (ru) 2005-08-10
KR100992850B1 (ko) 2010-11-09
EP1436322B1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
IL195892A (en) Pre-concentrates in the form of micro-emulsions of new cyclospores analogues
PY0225477A (es) Nuevas formulaciones de analogos de ciclosporina
UY27586A1 (es) Cis- imidaxolinas
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
PA8551001A1 (es) Nuevos compuestos
ATE488233T1 (de) Verminderung der nebenwirkungen bei der oxybutynin-therapie
SE0003449L (sv) Cancerhämmande kompositioner
DE60138222D1 (de) Modulierung von il-2 und il-15 vermittelten t zellantworten
UY27342A1 (es) Agente anticolinérgico cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
FI945619A0 (fi) Syklosporiinia sisältävät nestemäiset valmisteet ja menetelmä niiden valmistamiseksi
GT199900203A (es) Composiciones de celecoxib.
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
MX9307555A (es) Derivados de paclitaxel y formulaciones farmaceuticas que los contienen.
UY27553A1 (es) Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno
ATE537844T1 (de) Dauerhafte lokalanästhetische zusammensetzung mit saib
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
AR027360A1 (es) Composicion farmaceutica
HUP0400115A2 (hu) Gyógyászati készítmény fulvesztrant intramuszkuláris beadására
AR046226A1 (es) Formulaciones farmaceuticas que contienen saborizante con caracteristicas farmaceuticas mejoradas
PE20231943A1 (es) Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma
ES2136198T3 (es) Composiciones rectales que contienen odansetron en forma de su base libre.
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
YU32904A (sh) Novi analog ciklosporina za formiranje mikroemulzionih prekoncentrata